Functional expression of transient receptor potential vanilloid-related channels in chronically hypoxic human

Yue Xiu Wang1, Jun Wang, Cong Wang

  • 1Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, People's Republic of China.

Insights

Chronic hypoxia enhances human pulmonary artery smooth muscle cell proliferation via TRPV1 channels. Inhibiting TRPV1 with capsazepine blocks this effect, suggesting TRPV1

Area of Science:

  • Physiology
  • Molecular Biology
  • Cell Biology

Background:

  • Transient receptor potential vanilloid (TRPV) channels are crucial nonselective cation channels involved in various physiological processes.
  • TRPV channel subtypes are expressed in different tissues, playing roles in cellular function.
  • Pulmonary artery smooth muscle cells (PASMCs) are key regulators of vascular tone and proliferation.

Purpose of the Study:

  • To investigate the role of TRPV channels in hypoxia-induced proliferation of human PASMCs.
  • To explore the potential signaling pathway involved in this process.

Main Methods:

  • Gene and protein expression analysis using RT-PCR, real-time PCR, and Western blot.
  • Cell proliferation assessment using a hemocytometer.
  • Intracellular calcium ([Ca2+]cyt) measurement via digital imaging systems.
  • Pharmacological inhibition using capsazepine, a TRPV1 channel inhibitor.

Main Results:

  • TRPV1-4 mRNA detected in human PASMCs; chronic hypoxia upregulated TRPV1 gene and protein expression.
  • Chronic hypoxia significantly enhanced PASMC proliferation, resting [Ca2+]cyt, and capacitative Ca2+ entry.
  • Capsazepine dose-dependently inhibited hypoxia-induced proliferation and calcium signaling.
  • TRPV1 expression and function are upregulated by chronic hypoxia in human PASMCs.

Conclusions:

  • TRPV1 channels are implicated in the proliferation of human PASMCs under chronic hypoxic conditions.
  • TRPV1 may act as a critical pathway or mediator in chronic hypoxia-induced PASMC proliferation.
  • Targeting TRPV1 could offer therapeutic potential for pulmonary vascular diseases associated with hypoxia.

Related Concept Videos